Tenderwize
Wróć do wyszukiwania

Open-house rebate agreement for Anakinra

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Aug 03, 2027 · 340 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Anakinra, ATC L04AC03

62/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

62 / 100

Złożoność

58 / 100

Czynniki ryzyka

The notice explicitly says the contract documents must be submitted through the communication area in the DTVP portal a...

Only pharmaceutical companies are eligible as potential contract partners, and suitability must be proven by a signed d...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Sep 2027
  • Non-exclusive rebate agreements for the active substance Anakinra, ATC L04AC03.
  • Open-house model with identical, non-negotiable contract terms for all eligible pharmaceutical companies.
Pokaż pełne podsumowanie

Open-house supply arrangement for pharmaceutical products: non-exclusive rebate agreements for Anakinra (ATC L04AC03) offered by AOK Bayern to all interested pharmaceutical companies meeting the stated suitability requirement. This is explicitly described as an open-house model, not a competitive award procedure, with identical non-negotiable contract terms and no selection among bidders. Contracting is possible during the term, with the earliest start on 2025-10-01 and latest contract conclusion by 2027-08-03. Submission can be paper or electronic via DTVP, but the contract documents must be submitted through the communication area, not the offer area.

Ryzyka

The notice explicitly says the contract documents must be submitted through the communication area in the DTVP portal a...

Only pharmaceutical companies are eligible as potential contract partners, and suitability must be proven by a signed d...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
  • The contract must be submitted signed; signatory authority must be evidenced by the commercial register extract or a power of attorney must be provided.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreement for Anakinra

Single lot for non-exclusive pharmaceutical rebate agreements concerning Anakinra, ATC L04AC03. Scope is pharmaceutical supplies under an open-house model; contract terms are pre-set and not individually negotiable. The lot is for Germany, with performance in Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Sep 2025 - Sep 2027

Kategoria

Pharmaceutical products

Termin

Deadline Aug 03, 2027

Szczegóły zamówienia

Data publikacji
13 Aug 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
532705-2025

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30